Alemtuzumab for the treatment of B cell chronic lymphocytic leukemia
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000244
English, French
Authors' objectives:
To summarize the available information on the use of alemtuzumab (Trade Name: MabCampath; manufactured by Ilex Pharmaceuticals) for the treatment of B cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
Authors' recommendations:
Alemtuzumab was approved in the US in 2001 as last-line therapy in patients with B cell chronic lymphocytic leukemia. Deaths and serious morbidity related to the use of the drug were reported in two uncontrolled trials; in the setting of malignant diseases, however, this toxicity may be considered acceptable.
There is no direct evidence suggesting an increased survival with this new drug compared to, or combined with, first- or second-line agents. Its approval in the US was conditional upon the manufacturer conducting a comparative trial against chlorambucil; once results are available, alemtuzumab's place in therapy may become clearer.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Antineoplastic Agents
- Leukemia, Lymphocytic, Chronic, B-Cell
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.